A protective device that has not shown it protects patients routinely

Cardiovascular medicine · Source date: November 2026 journal issue; indexed by November 2 · Evidence: Systematic review and meta-analysis of 8 RCTs · Primary source

When aortic valves are replaced through a catheter, clinicians worry about embolic material reaching the brain. Cerebral embolic-protection devices are designed to catch debris during transcatheter aortic valve replacement (TAVR). Their mechanism is plausible, but a device must ultimately reduce strokes that patients experience. This new synthesis brings together eight randomized trials and 11,692 participants.

Routine protection was not associated with a statistically significant reduction in stroke within two to five days (risk ratio 0.95; 95% CI 0.75–1.19) or at 30 days (RR 0.93; 95% CI 0.57–1.53). Estimates for disabling stroke were imprecise, and the pooled studies differed by device and context. The result does not exclude narrower benefits in carefully selected high-risk patients, but it weakens the case for routine use as a default intervention.

A device can catch debris without reducing strokes. Local risks, patient selection and procedural harms matter when deciding whether a device deserves routine use.

appraisal and patient selection still matter.